Rivenprost (Synonyms: ONO-4819) |
Catalog No.GC44845
One-Click Copy Product Info
|
Prostaglandin E2 activates four distinct G protein-coupled receptors, EP1-4.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 256382-08-8
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Prostaglandin E2 activates four distinct G protein-coupled receptors, EP1-4. Rivenprost is a potent and selective agonist for the EP4 receptor (Ki = 0.7, 56, 620, and >10,000 nM for EP4, EP3, EP2, and EP1, respectively). It has been used to promote EP4-mediated bone formation, prevent bone loss related to osteoporosis, drive osteoblast differentiation, and stabilize bone implants.[1][2][3][4][5] Rivenprost has also been used to support wound healing.[6]
Reference:
[1]. Yoshida, K., Oida, H., Kobayashi, T., et al. Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation. Proceedings of the National Academy of Sciences of the United States of America 99(7), 4580-4585 (2002).
[2]. Ninomiya, T., Hosoya, A., Hiraga, T., et al. Prostaglandin E2 receptor EP4-selective agonist (ONO-4819) increases bone formation by modulating mesenchymal cell differentiation. European Journal of Pharmacology 650, 396-402 (2011).
[3]. Ito, M., Nakayama, K., Konaka, A., et al. Effects of a prostaglandin EP4 agonist, ONO-4819, and risedronate on trabecular microstructure and bone strength in mature ovariectomized rats. Bone 39, 453-459 (2006).
[4]. Nakagawa, K., Imai, Y., Ohta, Y., et al. Prostaglandin E2 EP4 agonist (ONO-4819) accelerates BMP-induced osteoblastic differentiation. Bone 41, 543-548 (2007).
[5]. Hayashi, K., Fotovati, A., Abu Ali, S., et al. Effect of a prostaglandin EP4 receptor agonist on early fixation of hydroxyapatite/titanium composite- and titanium-coated rough-surfaced implants in ovariectomized rats. J.Biomed.Mater.Res.A 92(3), 1202-1209 (2010).
[6]. Honma, Y., Arai, I., Hashimoto, Y., et al. Prostaglandin D2 and prostaglandin E2 accelerate the recovery of cutaneous barrier disruption induced by mechanical scratching in mice. European Journal of Pharmacology 518, 56-62 (2005).
| Cas No. | 256382-08-8 | SDF | |
| Synonyms | ONO-4819 | ||
| Chemical Name | 4-[[2R-[3R-hydroxy-2-[3S-hydroxy-4-[3-(methoxymethyl)phenyl]-1R-buten-1E-yl]-5-oxocyclopentyl]ethyl]thio]-butanoic acid, methyl ester | ||
| Canonical SMILES | O=C1[C@H](CCSCCCC(OC)=O)[C@@H](/C=C/[C@@H](O)CC2=CC(COC)=CC=C2)[C@H](O)C1 | ||
| Formula | C24H34O6S | M.Wt | 450.6 |
| Solubility | 30mg/ml in ethanol, or in DMF, 20mg/mL in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.2193 mL | 11.0963 mL | 22.1926 mL |
| 5 mM | 443.9 μL | 2.2193 mL | 4.4385 mL |
| 10 mM | 221.9 μL | 1.1096 mL | 2.2193 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solution in methyl acetate
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 35 reference(s) in Google Scholar.)